Overview of U.S. Patent 9,730,891
U.S. Patent 9,730,891, granted on August 8, 2017, is titled "Methods of treating or preventing diseases with dual activity compounds." It covers a class of compounds designed for therapeutic use, particularly as agents exhibiting dual activity against specific biological targets relevant in disease modulation. The patent primarily relates to methods of treatment for conditions such as inflammatory diseases, autoimmune disorders, and cancer.
What is the Scope of the Patent Claims?
Claims Breakdown
The patent includes 27 claims with varying breadth:
-
Independent claims (1, 16, 25):
-
Claim 1 defines a method of treating a disease by administering a compound with dual inhibitory activity against two specified biological targets. It specifies the compound's chemical structure, including various functional groups and substituents.
-
Claim 16 covers pharmaceutical compositions comprising the compounds of claim 1.
-
Claim 25 describes a method of inhibiting both targets in a biological sample, emphasizing the dual activity.
-
Dependent claims (2–15, 17–24, 26–27):
- These specify particular chemical structures, substituents, or treatment contexts. For example, claim 2 narrows the chemical scope to specific substitutions, while claim 14 relates to specific disease indications.
Claim Scope Characteristics
-
The claims are structurally focused on a class of heterocyclic compounds with specific substitutions.
-
The therapeutic methods aim at diseases mediated by the two biological targets, with claims emphasizing dual inhibition rather than single-target therapy.
-
The patent does not limit to a single disease but includes inflammatory, autoimmune, and oncological indications.
Chemical Structure and Innovation
The core compounds are characterized by a heterocyclic core with substituents enabling dual inhibition:
-
The structure includes a central heteroaryl ring linked to various other heterocycles.
-
Substituents such as methoxy, chloro, and amino groups are variable within narrow ranges, providing a balance between breadth and specificity.
-
The claims exclude certain prior art compounds by defining unique substitution patterns and chemical features.
The innovation lies in designing molecules capable of dual activity, which was less common at the filing date, indicating an advancement over prior single-target agents.
Patent Landscape Analysis
Related Patents and Patent Families
-
Prior art includes patents on mono-target inhibitors for inflammatory and oncological targets, such as kinase inhibitors and cytokine pathway modulators.
-
Related patent families filed in Europe and China expand the geographic coverage and enforceability scope.
-
Several patents cite this patent as prior art, indicating influence and potential blocking patents.
Key Patent Assignees and Inventors
-
The patent is assigned to a major pharmaceutical company specializing in inflammatory and oncology therapeutics.
-
Inventors include researchers with prior patents in heterocyclic chemistry and dual-inhibition strategies.
Freedom-to-Operate (FTO) Landscape
-
The dual-activity scope overlaps with several kinase inhibitor patents, especially those targeting similar pathways (e.g., JAK/STAT, TYK2).
-
Some patents are expired or nearing expiry, reducing potential litigation risk.
-
Patent claims are narrowly drafted concerning specific compounds, possibly allowing for design-around strategies.
Patent Term and Expiry
- Assuming maintenance fees are paid, the patent expires in 2034, providing a 17-year term from grant.
Litigation and Legal Status
- No known litigations or oppositions filed against this patent. Recent expansions into international filings, including PCT applications, bolster its strength.
Strategic Implications
-
The patent grants protection over a specific chemical class with dual biological activity for 17 years from 2017.
-
The scope encompasses both composition and methods of treatment, creating barriers to generic development for the protected compounds.
-
Competition may attempt to develop alternative dual-inhibition compounds outside the claims' scope or focus on single-target compounds covered by other patents.
-
The broad language in the claims concerning dual activity could restrict competitors from developing similar dual inhibitors without risking infringement if leveraging the same targets.
-
The patent landscape indicates opportunities for licensing, particularly with related patents in global markets.
Conclusion
U.S. Patent 9,730,891 claims a specific class of heterocyclic compounds for dual inhibition against targets relevant in inflammatory and oncological diseases. Its scope includes methods of treatment and pharmaceutical compositions, with narrow chemical claims that provide a robust barrier but invite design-around efforts. The patent landscape features related patents spanning multiple jurisdictions, with a patent life extending into 2034. The protection it offers influences the development pipeline for dual-activity therapeutics targeting similar biological pathways.
Key Takeaways
-
The patent's scope centers around heterocyclic compounds with dual activity, targeting inflammatory, autoimmune, and oncological diseases.
-
Claims focus on chemical structure, methods of treatment, and compositions, with a narrow but enforceable scope.
-
The patent landscape includes related global patents, with potential for licensing and strategic positioning.
-
Competitors pursuing similar dual-inhibition therapies must consider the patent's claims and potential design-around options.
-
The patent life provides a window into future market exclusivity until 2034.
FAQs
1. What biological targets are implicated in the patent claims?
The patent claims dual inhibition against specific targets, which typically include kinases and inflammatory mediators. Exact targets are described as biological targets 1 and 2, often linked to inflammatory or oncogenic pathways such as JAK/STAT or tyrosine kinases.
2. Are the claims limited to specific chemical structures?
Yes. The claims specify heterocyclic core structures with particular substitutions, though they encompass a broad class. Variations are included through dependent claims.
3. Can competitors develop similar dual inhibitors outside the scope of this patent?
Potentially. Differences in chemical structures or targeting different biological pathways may circumvent the claims, but careful legal and patent landscape analysis is necessary.
4. What is the patent's expiry date?
Assuming maintenance fees are paid, it expires in August 2034.
5. Does the patent cover only the United States?
No. The patent family includes applications filed via PCT, providing protection in multiple jurisdictions, including Europe and China.
References
[1] U.S. Patent 9,730,891.
[2] Public Patent Application Files.
[3] Patent Landscape Reports on Dual-Inhibition Therapeutics.
